Skip to main content

Nanogen Gets CDC Contract to Develop Flu Tests

NEW YORK (GenomeWeb News) – Nanogen said today that it has been awarded a two-year, $10.4 million contract from the US Centers for Disease Control and Prevention to develop multi-analyte molecular diagnostic tests for influenza.
 
Under the contract, San Diego-based Nanogen will develop a rapid molecular test that simultaneously detects and differentiates influenza type A and type B, seasonal flu (H1N1 and H3N2) strains, and respiratory syncytial virus. The firm also will develop a secondary test for avian flu strains including H5N1, H7N1, and H9N1, to be available for samples testing positive for flu A but negative for seasonal flu.
 
Nanogen said it would develop the tests in combination with the Medical College of Wisconsin and HandyLab, and it expects the tests to be more sensitive and quicker than currently available molecular diagnostic assays for flu. Nanogen said that the proposal presented to the CDC said that it would use its MGB probe technology in combination with HandyLab’s Raider instrument, a microfluidic real-time PCR-based system.
 
Nanogen also is developing a rapid, point-of-care flu test for the CDC, under a contract signed in December 2006.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.